CASI Pharmaceuticals (CASI) Earning Somewhat Favorable Media Coverage, Study Shows

News stories about CASI Pharmaceuticals (NASDAQ:CASI) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CASI Pharmaceuticals earned a news impact score of 0.06 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.1636105488991 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

CASI has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of CASI Pharmaceuticals in a report on Tuesday, January 16th. Maxim Group set a $4.00 price target on CASI Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 14th. Finally, BidaskClub downgraded CASI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday.

Shares of CASI Pharmaceuticals (NASDAQ CASI) traded down $0.01 during midday trading on Friday, hitting $3.84. The stock had a trading volume of 93,398 shares, compared to its average volume of 274,736. CASI Pharmaceuticals has a 1-year low of $0.91 and a 1-year high of $4.84. The company has a market cap of $249.21, a P/E ratio of -32.00 and a beta of 0.71.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Insider Buying and Selling by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)

Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit